Sanofi has a new head of development, which the company confirmed on Wednesday with a short tweet: "Dietmar Berger, MD, PhD, joins #Sanofi as Head of Development, overseeing our clinical portfolio across all therapeutic areas and helping us bring transformative new medicines to patients."
Emergency on planet AMR: a vital pipeline to protect
OpinionThe recently released IACG report testifies that the antimicrobial resistance (AMR) problem is now receiving some echo at the political level. Literature exploring ways to fix the acknowledged market failure is growing. Stakeholder meetings deciphering the impact of the proposed models are being organised all over the world. Still, time is against us.
Researchers find clue to Parkinson’s gene therapy
Latest NewsAn enzyme that clears out alpha-synuclein from neurons may counteract Parkinson’s Disease, report researchers from ETH Zürich and Novartis.
Chikungunya vaccine developer Themis bags $21m
Latest NewsUnder a partnering ageement with CEPI, Themis Bioscience will receive $21m to push pivotal testing of MV-CHIK, its Chikungunya vaccine candidate.
Genetically modified fungus stops malaria mosquitoes
Latest NewsA fungus that produces an insecticide can stop the spread of Anopheles mosquito, which causes malaria.
Abacus Medicine postpones IPO
Latest NewsEuropean pharmaceutical parallel trade company Abacus Medicine A/S has postponed its planned Initial Public Offering (IPO), due to "unfavourable market environment".
Dietmar Berger returns to big pharma
AppointmentsSanofi has a new head of development, which the company confirmed on Wednesday with a short tweet: "Dietmar Berger, MD, PhD, joins #Sanofi as Head of Development, overseeing our clinical portfolio across all therapeutic areas and helping us bring transformative new medicines to patients."
Biotage gets new CEO
AppointmentsTomas Blomquist has been appointed as the new CEO and President of Biotage AB.
Make leukaemia therapy safer
Latest NewsA Belgian-British-Australian research team has created a safer version of a therapy that combats the aggressive form of a blood cancer called acute lymphoblastic leukemia (ALL) while avoiding toxicity.
Nanobiotix spins out Curadigm
Latest NewsCancer-focussed Nanobiotix SA has spun out Curadigm, which offers a platform to improve the bioavailability of nanomedicines by reducing liver and spleen toxicity and accumulation.
Double win for Novartis
Latest NewsIt was a good day for Novartis: A second drug with huge selling potential has been approved for the US market. The FDA gave the go ahead for breast cancer drug Piqray (alpelisib), the first and only treatment developed specifically for patients with a PIK3CA mutation in HR+/HER2-advanced breast cancer.